Assessment of autoantibodies against 21-hydroxylase in the diagnosis of primary autoimmune adrenal insufficiency

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access



Primary adrenal insufficiency  is manifested by a deficiency of adrenal cortex hormones and can lead to a life-threatening condition. Early diagnosis is key to patient survival. Auto-antibodies to one of the adrenal steroidogenesis enzymes, 21-hydroxylase, are an immunological marker of autoimmune adrenal insufficiency. On the one hand, the study of antibodies to 21-hydroxylase is a method that helps establish the etiology of the disease — the autoimmune genesis of adrenal gland damage. On the other hand, the determination of autoantibodies to 21-hydroxylase is the only prognostic factor of the risk of adrenal insufficiency, which makes it possible  to prevent the development of acute adrenal crisis.

 The article provides a brief literature review on autoantibodies to 21-hydroxylase and the pathogenesis of autoimmune adrenal insufficiency, and a series of clinical cases that illustrates the significant role of autoantibodies to 21-hydroxylase in diagnosis of adrenal insufficiency.

Full Text

About the authors

Leila Sozaeva

Endocrinology Research centre

Author for correspondence.
ORCID iD: 0000-0002-5650-1440
SPIN-code: 9983-5662
Scopus Author ID: 56730766000
ResearcherId: C-7231-2012

Russian Federation, г.Москва, Ул.Дмитрия Ульянова, 11

Старший научный сотрудник

Nadezhda Makazan

Endocrinology Research centre

ORCID iD: 0000-0003-3832-6367
SPIN-code: 7156-6517
Scopus Author ID: 57192199028
ResearcherId: B-8929-2019

Russian Federation, г.Москва, Ул.Дмитрия Ульянова, 11

Старший научный сотрудник

Larisa Nikankina

Endocrinology Research centre

ORCID iD: 0000-0002-1120-8240
SPIN-code: 2794-0008
Scopus Author ID: 57190192821

Russian Federation, г.Москва, Ул.Дмитрия Ульянова, 11

заведующий клинико-диагностической лабораторией

Natalya Malysheva

Endocrinology Research centre

ORCID iD: 0000-0001-6630-227X
SPIN-code: 5793-2550
Scopus Author ID: 57197834989

Russian Federation, г.Москва, Ул.Дмитрия Ульянова, 11

ведущий научный сотрудник

Ekaterina Kuvaldina

Russian Children's Clinical Hospital, Moscow

ORCID iD: 0000-0001-5466-4644
SPIN-code: 3602-5578

Russian Federation, Москва, Ленинский проспект 117

врач- детский эндокринолог

Maria Kareva

Endocrinology Research centre

ORCID iD: 0000-0003-1320-6561
SPIN-code: 5221-4235
Scopus Author ID: 57192249938

Russian Federation, г.Москва, Ул.Дмитрия Ульянова, 11

заведующая детским отделением опухолей эндокринной системы

Elizaveta Orlova

Endocrinology Research centre

ORCID iD: 0000-0001-6196-5322
SPIN-code: 5221-4235
Scopus Author ID: 19836983300

Russian Federation, г.Москва, Ул.Дмитрия Ульянова, 11

Ведущий научный сотрудник

Valentina Peterkova

Endocrinology Research centre

ORCID iD: 0000-0002-5507-4627
SPIN-code: 4009-2463
Scopus Author ID: 6701824828
ResearcherId: B-1344-2017

Russian Federation, г.Москва, Ул.Дмитрия Ульянова, 11

научный руководитель Института детской эндокринологии


  • Дедов И. И., Петеркова В. А.. Федеральные клинические рекомендации (протоколы) по ведению детей с эндокринными заболеваниями. Москва: Практика; 2014. 442 с. [Dedov I.I., Peterkova V.A. Federalniye klinicheskiye recomendatsii po vedeniyu detey s endocrinnimi zabolevaniyami. Moscow: practica: 2014. 442c (in Russ.)]
  • Dunlop D. Eighty-six cases of Addison’s disease. Br Med J1963;2(5362):887–91. doi: 10.1136/bmj.2.5362.887.
  • Betterle C, Scarpa R, Garelli S. et al. Addison’s disease: a survey on 633 patients in Padova. Eur J Endocrinol. 2013 ;169(6):773–84. doi: 10.1530/EJE-13-0528.
  • Erichsen MM, Løvås K, Skinningsrud B et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab. 2009 ;94(12):4882–90. doi: 10.1210/jc.2009-1368.
  • Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the Prevalence of Addison’s Disease Underestimated? The Journal of Clinical Endocrinology & Metabolism. 1999;84(5):1762–1762. doi: 10.1210/jcem.84.5.5677-7.
  • Willis AC, Vince FP. The prevalence of Addison’s disease in Coventry, UK. Postgraduate Medical Journal. 1997 ;73(859):286–8. doi: 10.1136/pgmj.73.859.286.
  • Betterle C, Morlin L. Autoimmune Addison’s disease. Endocr Dev. 2011 ;20:161–72. doi: 10.1159/000321239.
  • Orlova EM, Sozaeva LS, Kareva MA, Oftedal BE, Wolff ASB, Breivik L, и др. Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1. The Journal of Clinical Endocrinology & Metabolism. 2017 ;102(9):3546–56. doi: 10.1210/jc.2017-00139.
  • Bornstein SR, Allolio B, Arlt W et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2016 ;101(2):364–89. doi: 10.1210/jc.2015-1710.
  • Extract of Suprarenal Cortex in the Treatment of Addison’s Disease. Edinb Med J. 1932 ;39(4):268–70.
  • Anderson JR, Goudie RB, Gray K, Timbury GC. Auto-antibodies in addison’s disease. The Lancet. 1957 ;269(6979):1123–4. doi: 10.1016/s0140-6736(57)91687-2.
  • Winqvist O, Karlsson FA, Kämpe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison’s disease. Lancet. 1992 ;339(8809):1559–62. doi: 10.1016/0140-6736(92)91829-w.
  • Boscaro M, Betterle C, Volpato M et al. Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo. The Journal of Clinical Endocrinology & Metabolism. 1996 ;81(8):2801–4. doi: 10.1210/jcem.81.8.8768833.
  • Rottembourg D, Deal C, Lambert M et al. 21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison’s disease. Journal of Autoimmunity. 2010 ;35(4):309–15. doi: 10.1016/j.jaut.2010.07.001.
  • Wolff ASB, Mitchell AL, Cordell HJ et al. CTLA-4 as a genetic determinant in autoimmune Addison’s disease. Genes & Immunity. 2015 ;16(6):430–6. doi: 10.1038/gene.2015.27.
  • Blomhoff A, Lie BA, Myhre AG et al. Polymorphisms in the Cytotoxic T Lymphocyte Antigen-4 Gene Region Confer Susceptibility to Addison’s Disease. The Journal of Clinical Endocrinology & Metabolism. 2004 ;89(7):3474–6. doi: 10.1210/jc.2003-031854.
  • Salmond RJ, Brownlie RJ, Morrison VL, Zamoyska R. The tyrosine phosphatase PTPN22 discriminates weak self peptides from strong agonist TCR signals. Nature Immunology. 2014 ;15(9):875–83. doi: 10.1038/ni.2958.
  • Skinningsrud B, Husebye ES, Gervin K et al. Mutation screening of PTPN22: association of the 1858T-allele with Addison’s disease. European Journal of Human Genetics. 2008 ;16(8):977–82.
  • Mitchell AL, Cordell HJ, Soemedi R et al. Programmed Death Ligand 1 ( PD - L1 ) Gene Variants Contribute to Autoimmune Addison’s Disease and Graves’ Disease Susceptibility. The Journal of Clinical Endocrinology & Metabolism. 2009 ;94(12):5139–45. doi: 10.1210/jc.2009-1404.
  • de Filette J, Andreescu C, Cools F, Bravenboer B, Velkeniers B. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Hormone and Metabolic Research. 2019 ;51(03):145–56. doi: 10.1055/a-0843-3366.
  • Hellesen A, Bratland E, Husebye ES. Autoimmune Addison’s disease – An update on pathogenesis. Annales d’Endocrinologie. 2018 ;79(3):157–63. doi: 10.1016/j.ando.2018.03.008.
  • Eriksson D, Bianchi M, Landegren N et al. Common genetic variation in the autoimmune regulator (AIRE) locus is associated with autoimmune Addison’s disease in Sweden. Scientific Reports. 2018;8(1). doi: 10.1038/s41598-018-26842-2.
  • Betterle C, Garelli S, Presotto F, Furmaniak J. From Appearance of Adrenal Autoantibodies to Clinical Symptoms of Addison’s Disease: Natural History. В: Arvat E, Falorni A, Frontiers of Hormone Research . Karger AG; 2016;46:133–45. doi: 10.1159/000443872.



Abstract - 123

PDF (Russian) - 0



Copyright (c) Sozaeva L., Makazan N., Nikankina L., Malysheva N., Kuvaldina E., Kareva M., Orlova E., Peterkova V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies